Funder: National Institutes of Health

Due Dates: June 18, 2025 (New/Renewal/Resubmission/Revision) | August 21, 2025 (AIDS) | October 21, 2025 (New/Renewal/Resubmission/Revision) | December 22, 2025 (AIDS) | February 11, 2026 (New/Renewal/Resubmission/Revision) | April 21, 2026 (AIDS) | June 18, 2026 (New/Renewal/Resubmission/Revision) | August 21, 2026 (AIDS) | October 21, 2026 (New/Renewal/Resubmission/Revision) | December 23, 2026 (AIDS) | February 11, 2027 (New/Renewal/Resubmission/Revision) | April 23, 2027 (AIDS) | June 17, 2027 (New/Renewal/Resubmission/Revision) | August 23, 2027 (AIDS) | October 21, 2027 (New/Renewal/Resubmission/Revision) | December 23, 2027 (AIDS)

Funding Amounts: Up to $400,000 direct costs/year for R61 (up to 2 years) and R33 (up to 2 years); max combined project period 3 years; R33 phase requires 0.25:1 non-federal cash match.

Summary: Funds early-stage translational research to identify and validate small molecule, biologic, and combination product therapies for heart, lung, blood, and sleep disorders.

Key Information: Clinical trials are not allowed; R33 phase requires both cost matching and an Accelerator Partner for commercialization guidance.